Cargando…
Computational modeling and experimental validation of the EPI-X4/CXCR4 complex allows rational design of small peptide antagonists
EPI-X4, a 16-mer fragment of albumin, is a specific endogenous antagonist and inverse agonist of the CXC-motif-chemokine receptor 4 (CXCR4) and thus a key regulator of CXCR4 function. Accordingly, activity-optimized synthetic derivatives of EPI-X4 are promising leads for the therapy of CXCR4-linked...
Autores principales: | Sokkar, Pandian, Harms, Mirja, Stürzel, Christina, Gilg, Andrea, Kizilsavas, Gönül, Raasholm, Martina, Preising, Nico, Wagner, Manfred, Kirchhoff, Frank, Ständker, Ludger, Weidinger, Gilbert, Mayer, Benjamin, Münch, Jan, Sanchez-Garcia, Elsa |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8458281/ https://www.ncbi.nlm.nih.gov/pubmed/34552197 http://dx.doi.org/10.1038/s42003-021-02638-5 |
Ejemplares similares
-
An optimized derivative of an endogenous CXCR4 antagonist prevents atopic dermatitis and airway inflammation
por: Harms, Mirja, et al.
Publicado: (2021) -
Development
of N-Terminally Modified Variants
of the CXCR4-Antagonistic Peptide EPI-X4 for Enhanced Plasma Stability
por: Harms, Mirja, et al.
Publicado: (2023) -
Absence of the CXCR4 antagonist EPI-X4 from pharmaceutical human serum albumin preparations
por: Gilg, Andrea, et al.
Publicado: (2021) -
Microtiter plate-based antibody-competition assay to determine binding affinities and plasma/blood stability of CXCR4 ligands
por: Harms, Mirja, et al.
Publicado: (2020) -
Advanced EPI-X4 Derivatives Covalently Bind Human Serum Albumin Resulting in Prolonged Plasma Stability
por: Rodríguez-Alfonso, Armando, et al.
Publicado: (2022)